ClinicalTrials.gg
RecruitingNCT05246644IVACS-PilotUpdated Feb 28, 2024

IV Acetaminophen After Cardiac Surgery - PILOT

A Phase 3 interventional study of acetaminophen in Delirium, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Recruiting at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-28.

Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
900
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Delirium with a site in Canada — 16 open to participants now, 24 under way, 2 of them phase 3. Delirium · Canada.

Planned enrollment
7th of 53
900 · median 88
Started
2023
with 3 others
Phase 3
7 of 80
2 open now
Primary completion
2024-09
later than 4 of 23 live
Registered
65th of 80
by date

Among the 80 studies in Delirium with a site in Canada, this one is the 7th largest by planned enrollment of the 53 interventional ones that give a count, is one of 4 that started in 2023, is one of 7 in phase 3, reaches primary completion later than 4 of the 23 other live ones, and was the 65th registered.

Delirium

934 studies on the registry are indexed under Delirium; 188 are open to participants now.

Browse Delirium studies →

Open to participants now

16 of the 80 studies in Delirium with a site in Canada are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 124 Delirium studies recruiting now, 96 (77%) set no upper age limit and 8 (6%) stop at 75 or younger; 8 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Delirium with a site in Canada, or all of them as a file.
02

Study summary

Double blind double dummy of Intravenous Acetaminophen and oral acetaminophen placebo versus IV placebo versus oral acetaminophen in patients following cardiac surgery. The primary endpoint is development of Delirium during the post-operative stay.

Read the detailed description

The study is randomized, double-blinded, and multicentre. Enrollment includes patients 18 years or older who are going for aortocoronary bypass surgery, single valve, or bypass and single valve. The intervention is blinded IV acetaminophen and blinded oral active or placebo acetaminophen . The study will start with a pilot trial of 120 patients at 4 centers- 30 at each site, 15 per group. The pilot is a vanguard. If the pilot shows appropriate compliance with the protocol, reliable blinding and appropriate enrolment, the results will not be unblinded but rolled into the full study. Stratification will be by site and age \< 60 or >= 60.

03

Conditions studied

  • Delirium

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • subjects > 18 years of age undergoing elective aortocoronary bypass, single valve replacement or single valve and aortocoronary bypass surgery

Exclusion criteria

Exclusion Criteria:

    • Refusal by surgeon for inclusion of the patient

      • Requested late extubation by anesthesia or surgeon
      • Intra-aortic balloon pump
      • Sensitivity to acetaminophen
      • Pre-operative cognitive dysfunction
      • Psychiatric history with active treatment
      • Parkinson's disease
      • Alzheimer's disease
      • Medication for cognitive decline
      • History of recent seizures
      • Recent history of alcohol misuse
      • less than 30 ml/min
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
900 participants (estimated)

Study arms

  • Experimental
    Intravenous Acetaminophen

    subjects will receive IV acetaminophen and a placebo oral acetaminophen starting immediately after surgery and for 8 doses

    Drug: acetaminophen

  • Active comparator
    Oral acetaminophen

    subjects will receive a placebo for IV acetaminophen and active oral acetaminophen starting immediately after surgery and for 8 doses

    Drug: acetaminophen

Interventions

  • we will use IV acetaminophen and an oral placebo or IV placebo and active oral acetaminophen

    Also known as: placebo

06

What researchers measure

Primary outcomes

  1. Development of delirium post operatively

    Incidence of delirium will be analyzed between patients treated with IV or oral acetaminophen, measured from 24 hours post-operation and daily until discharge. Delirium will be defined as an acute change in pre-operative baseline condition with additional features of inattention and either disorganized thinking and altered loss of consciousness, as defined by the Confusion Assessment Method (CAM) or CAMICU when in the intensive care unit

    Time frame: up to 7 days post operatively

Secondary outcomes

  1. total opioid usage

    tabulation of all opioids normalized to morphine

    Time frame: up to 7 days post-operatively

  2. Numeric pain rating scale

    visual pain score from 1 to 10

    Time frame: up to 48 hours

  3. cognitive function

    change in cognitive function score by 2 based on the Montreal cognitive assessment

    Time frame: 7 days post-operative, 6 months and 1 year

  4. hospital length of stay

    Days until discharge

    Time frame: length of stay is measured from the day of surgery until the day of discharge from hospital in days

  5. Intensive care length of stay

    hours in ICU

    Time frame: ICU stay is measured from the hour of arrival in the ICU and until the patient leaves the ICU in hours

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Sep 2024, 15 months after the start.

Of 27 phase 3 interventional studies under Delirium, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 59. This study's planned 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2021
First posted
Feb 18, 2022
StartActual
Jun 6, 2023
Primary completionEst.
Sep 30, 2024
CompletionEst.
Dec 15, 2024
Last update
Feb 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05246644
Collaborators
Montreal Heart Institute, University of Manitoba, Canadian Institutes of Health Research (CIHR)
Responsible party
magder sheldon (Senior Physician, McGill University Health Centre/Research Institute of the McGill University Health Centre) — Principal investigator
First posted
Feb 18, 2022
Start date
Jun 6, 2023
Primary completion
Sep 30, 2024 (estimated)
Completion
Dec 15, 2024 (estimated)
Last update
Feb 28, 2024

Study contacts

sheldon magder, MD
Contact
sheldon.magder@mcgill.ca
5149475918

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion